Bone scan in metabolic bone diseases. Review by Abdelrazek, Saeid et al.
124
Nuclear Medicine Review 2012, 15, 2: 124–131
10.5603/NMR.2011.00022
Copyright © 2012 Via Medica
ISSN 1506–9680Review
Abstract
Metabolic bone disease encompasses a number of disorders 
that tend to present a generalized involvement of the whole 
skeleton. The disorders are mostly related to increased bone 
turnover and increased uptake of radiolabelled diphosphonate. 
Skeletal uptake of 99mTc-labelled diphosphonate depends pri-
marily upon osteoblastic activity, and to a lesser extent, skeletal 
vascularity. A bone scan image therefore presents a functional 
display of total skeletal metabolism and has valuable role to 
play in the assessment of patients with metabolic bone disor-
ders. However, the bone scan appearances in metabolic bone 
disease are often non-specific, and their recognition depends 
on increased tracer uptake throughout the whole skeleton. It 
is the presence of local lesions, as in metastatic disease, that 
makes a bone scan appearance obviously abnormal. In the 
early stages, there will be difficulty in evaluating the bone scans 
from many patients with metabolic bone disease. However, in 
the more severe cases scan appearances can be quite striking 
and virtually diagnostic.
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Introduction
Metabolic bone disease encompasses a number of disor-
ders that tend to present a generalized involvement of the whole 
skeleton. The disorders are mostly related to increased bone 
turnover and increased uptake of radiolabelled diphosphonate. 
Skeletal uptake of 99mTc-labelled diphosphonate depends primarily 
upon osteoblastic activity, and to a lesser extent, skeletal vascular-
ity [1]. A bone scan image therefore presents a functional display 
of total skeletal metabolism and has valuable role to play in the 
assessment of patients with metabolic bone disorders (Figure 1). 
However, the bone scan appearances in metabolic bone disease 
are often non-specific, and their recognition depends on increased 
tracer uptake throughout the whole skeleton [2]. It is the presence 
of local lesions, as in metastatic disease, that makes a bone scan 
appearance obviously abnormal. In the early stages there will be 
difficulty in evaluating the bone scans from many patients with 
metabolic bone disease. However, in the more severe cases scan 
appearances can be quite striking and virtually diagnostic.
Many of the metabolic bone diseases, with the exception of 
osteoporosis, are characterized by high bone turnover and are of-
ten associated with elevated levels of serum parathyroid hormone, 
which causes increased bone resorption. It is recognized that 
bone-seeking radiopharmaceuticals adsorb onto bone at sites of 
new bone formation, with particular affinity for areas where active 
mineralization is occurring.
The most important features of bone scintigraphy in metabolic 
diseases are its high sensitivity and its capacity to easily image 
the whole body. Currently, the main clinical value of bone scan in 
metabolic bone disease is the detection of focal conditions or focal 
complications of such generalized disease, its most common use 
being the detection of fractures in osteoporosis, pseudofractures in 
osteomalacia and evaluation of Paget’s disease.
99mTc diphosphonate bone scanning agents
Phosphate analogues can be labelled with technetium (99mTc) 
and are used for bone imaging because of their good localization 
in the skeleton and rapid clearance from soft tissues, and their 
uptake in bone is thought to reflect osteoblastic activity and to 
a lesser extent skeletal vascularity [1] (Figure 1). Skeletal uptake 
of tracer therefore reflects skeletal metabolism. Bone scintigraphy 
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is an highly sensitive method for demonstrating disease in bone, of-
ten providing earlier diagnosis or demonstrating more lesions than 
are found by conventional radiological methods. In the metabolic 
bone disorders recognition of generalized high uptake of the tracer 
depends upon a subjective evaluation of the scan, and it is also 
likely that lesions will be more difficult to recognize against high 
background uptake of tracer by the skeleton. 
The development of skeletal imaging agents has been focused 
around structural modification of methylene diphosphonate (MDP) 
molecule. The addition of hydroxyl group to the central carbon 
atom of MDP to produce hydroxymethylene diphosphonate 
(HMDP), or an additional methyl group to the hydroxylated cen-
tral carbon atom to produce 1-hydroxyethylidene diphosphonate 
(HEDP), produce significant differences in both the pharmacoki-
netics and osseous specificity of the agents. 
99mTc HEDP was the first diphosphonate to be introduced into 
clinical practice. 99mTc MDP is currently the most widely used bone 
scanning agent. It has higher bone uptake, higher whole body 
retention and faster blood clearance than 99mTc-HEDP. 99mTc-HMDP, 
has faster blood clearance and higher skeletal uptake than MDP. 
99mTc DPD, is the newest of the available diphosphonate, it has sig-
nificantly higher skeletal uptake than MDP.
Accurate quantitation of tracer uptake by bone is required for 
a positive identification of increased skeletal metabolic activity. Meas-
urement of 24-hours whole body retention (WBR) of Tc-HEDP, using 
a shadow shield, whole body monitor is a sensitive measure of ske-
letal metabolism and of value in the diagnosis of metabolic disease. 
The 24-hr value for WBR of Tc-99m-HEDP is a more conveni-
ent measurement than 8-hr value, in fact, almost 70% of an i.v. 
dose of 99mTc-HEDP is normally excreted through the urinary tract 
within 6 hr after injection. Therefore, by 24 hr the body burden of 
99mTc HEDP represents almost entirely skeletal uptake. The use of 
a whole body monitor to calculate the 24-hr WBR of 99mTc-HEDP 
provides an overall measurement of skeletal retention of radiop-
harmaceutical. Very high values for WBR of 99mTc-HEDP can be 
expected in any patient unable to excrete the tracer due to severe 
renal impairment, in patients with renal osteodystrophy the high 
retentions were largely due to increased skeletal uptake of the 
tracer. A high WBR of 99mTc-HEDP cannot differentiate between 
uremic patients with significant renal osteodystrophy and those 
with other form of severe renal impairment, but the bone scintigram 
clearly shows the high uptake and low soft-tissue back-ground 
typical of renal osteodystrophy. Elevated value for 24-hr whole 
body retention of 99mTc-HEDP correlate with condition known to 
cause increased bone turnover. 
WBR of diphosphonate is a simple non-invasive test that pro-
vides simple and sensitive measure of skeletal metabolism and can 
be used as a screening test for various metabolic disorders, and 
the patients with primary hyperparathyroidism, osteomalacia, renal 
osteodystrophy, and Paget’s disease can be clearly differentiated 
from a healthy population [3–5]. 
Pentavalent Technetium 99m (V) dimercaptosuccinic acid 
(99mTc- (V) DMSA) uptake has been reported in bone metasta-
ses [6], and in metabolic bone disease such as renal osteodys-
trophy [7] and Paget’s disease [8]. A striking similarity has been 
observed between 99mTc- (V) DMSA and 99mTc-MDP uptake for 
osseous and nonosseous lesions after a bone scan [6–9]. Higu-
chi et al. [7] described a patient with renal osteodystrophy with 
increased bone uptake on bone scintigraphy and 99mTc-(V) DMSA 
scans. They also concluded that 99mTc- (V) DMSA is a sensitive 
method for assessing patient response to therapy. 99mTc- (V) DMSA 
has early kidney uptake, and have a lower uptake in normal bone 
than in phosphate-based radiopharmaceuticals [10]. With those 
properties 99mTc- (V) DMSA can provide some complementary 
information in patients with renal disease who show evidence of 
a superscan. 99mTc- (V) DMSA scintigraphy could have a role in the 
evaluation of patients of equivocal bone scan findings who are 
thought to have superscan due to metastatic or metabolic disease. 
In a recent study with PET and Fluorine-18-Fluoride, local bone 
blood flow and fluoride index rate were quantified in patients in 
vivo. Metabolically active zones showed an increased flow, which 
allows for classification and monitoring of therapy in metabolic 
bone diseases [11].
Bone scan appearances
In more severe cases of metabolic bone disease characteristic 
patterns of bone scan abnormality are commonly seen [12]. It 
is including some of the following characteristics:
Figure 1. Patient A.C. 77 years old with normal bone scan
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1. “tie sternum”;
2. beading of the costochondral junction;
3. reduced renal activity, faint or absent kidney images;
4. increased tracer uptake in long bones;
5. increased tracer uptake in axial skeleton;
6. increased tracer uptake in periarticular areas;
7. prominence of calvaria and mandible;
These features are non- specific and, with the exception of 
absent kidney images, can all be seen in normal subjects. These 
features are frequently seen in adolescents, in whom the growing 
skeleton is metabolically active.
The “classic” bone scan appearance in metabolic bone 
disease is an image of excellent quality because of the high 
contrast between bone and soft tissue, in some cases the scan 
seems almost too good to be true (Figure 2). There is extremely 
high contrast between bone and adjacent soft tissue, and indi-
vidual metabolic features reflect increased tracer uptake at vari-
ous sites throughout the skeleton. Increased tracer uptake in the 
calvaria and mandible may on occasion be particularly prominent 
and produce striking images which are recognizable as abnor-
mal. Increased uptake in calvaria and mandible may be virtually 
pathognomonic of hyperparathyroidism. When there is increased 
skeletal avidity for tracer, renal images may appear faint or even 
be absent as a result of less tracer being available for excretion, 
with resulting heightened contrast between bone and kidneys. 
The costochondral junctions may be prominent, and this appear-
ances known as” beading” or the “rosary bead” appearance. In 
the sternum, characteristic appearances may often be seen, with 
a general increase of tracer uptake by the manubrium and, in 
the lateral borders of the body. Sometimes instead of uniformly 
increased uptake of tracer by sternum, only horizontal stripes were 
seen “Striped- tie” sign [13].
A hot patella on the bone scan is defined as uptake of tracer in 
the patella greater than that by the distal femur and proximal tibia 
of the ipsilateral leg. This also can be found in a wide variety of 
other conditions, including degenerative and metastatic disease. 
In hypertrophic pulmonary osteoarthropathy, involvement of the 
patella was noted in 50% of cases. When increased tracer uptake 
is seen in both patellae, this may well be a pathological feature, 
but it has no differential diagnostic value. However, skeletal uptake 
of tracer can be quantitated much more accurately by measure-
ment of 24-hr whole-body retention of 99mTc- diphosphonate, 
which has been shown to provide a sensitive means of identifying 
patients with increased bone turnover. 
The features of bone scan in some of the metabolic diseases:
Renal osteodystrophy
Renal osteodystrophy encompasses the changes in bone 
metabolism due to prolonged chronic renal disease. Osteoma-
lacia in renal dialysis is the result of aluminium toxicity. Some 
studies suggest that the bone disease can be observed in the 
absence of excess aluminium deposition, and that it could be 
due to the increased age of the patients receiving dialysis [14]. 
In patients with severe renal osteodystrophy, there is mark-
edly increased tracer uptake throughout the skeleton, the 
kidney appear faint and are frequently not visualized. There 
is extremely high contrast between bone and soft tissues, and 
the overall effect is to produce a superscan image [15–17]. 
The skull appearances may be virtually pathognomonic of 
severe hyperparathyroidism, with markedly increased uptake 
throughout the calvaria and mandible. Beading of the cos-
trochondral junctions and a “tie sternum” are also commonly 
seen. It is probable that the most of the scan findings are due 
to increased bone turnover resulting from secondary hyperpar-
athyroidism [18], but coexistent osteomalacia may contribute 
in some cases. The bladder may not be visualized because 
of failure to excrete tracer. Absence of the bladder helps to 
differentiate the bone scan in renal osteodystrophy from that 
in other metabolic disorders. The increased uptake in the long 
bones can be detected with quantitative imaging even when 
bone image seems to be visually normal [18]. False-negative 
results of superscan can arise in the presence of obstructive 
uropathy, and poor renal function can give rise to false-positive 
result. When aluminium toxicity occurs, bone scan shows poor 
uptake images with heightened background activity due to 
inhibition of tracer uptake by bone caused by the paucity of 
ostoeoblasts and newly formed osteoid [19].
In renal osteodystrophy bone scan uptake is usually diffuse 
and symmetric as opposed to advanced primary hyperparathy-
roidism where uptakes are often asymmetric because of cystic 
lesions and brown tumours [20]. Some studies comparing bone 
scan and conventional radiography have been performed. In 
one study by Fogelman and Carr, 99mTc-HEDP scan showed 
changes suggestive of a metabolic bone disorder in all 24 pa-
tients studied, whereas only 14 showed radiographic abnormali-
ties [5]. Another study of 30 patients with renal osteodystrophy 
showed a sensitivity of 83% using 99mTc-HEDP scan compared with 
Figure 2. Patient Z.W. 49 years old with typical superscan
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a 46% for radiography [18]. Therefore, it seems clear that in chronic 
renal failure the bone scan is more sensitive than radiography for 
detecting skeletal disease.
Osteosclerosis may occasionally be seen on radiographs of 
the spine in patients with renal osteodystrophy; the bone scan 
equivalent is linear areas of increased tracer uptake correspond-
ing to the cortical borders of vertebrae, against a background of 
generalized high uptake in the spine [2]. Sites of ectopic calcifica-
tion may be recognized, and the bone scan is more sensitive than 
routine radiography in identifying pulmonary calcification [21]. 
Osteomalacia
Osteomalacia results from vitamin D deficiency, which 
produces a profound mineralization defect. A common aetiol-
ogy is a lack of vitamin D caused by different factors. In severe 
cases there is massive excess of osteoid present with markedly 
reduced mineralization. The bone scan appearances in osteo-
malacia are usually abnormal. The scan findings, however, are 
non-specific and will demonstrate the classical characteristics of 
metabolic bone disease [22]. Generalized increased uptake, most 
visible at the periarticular zones, costochondral junctions, vertebral 
column, calvaria, mandible, and sternum; although bone scan 
in the early stages can be normal. It is not well known why bone 
scan shows an increased uptake in osteomalacia if a defect in 
mineralization occurs. It has been suggested that there may be so 
much osteoid that even if mineralization were slower than normal at 
any given site, the total area of mineralization would be increased 
[23]. It may be an effect of secondary hyperparathyroidism. Bone 
uptake of tracer reflects skeletal metabolism and that is likely to 
be primarily due to parathyroid hormone effect [12]. 
Pseudofractures (Looser’s zone or milkman’s fractures) are 
often detected early in the disease, and are usually symmetric and 
perpendicular to the bone surface. They are commonly found in 
the scapula, medial aspect of the femoral neck, pubic rami, ulna 
(proximal third), radius (distal third), ribs, clavicle, metacarpals, 
metatarsals, and phalanges. Pulsating vessels on the softened 
bone cortex have been suggested to be the origin of pseudo-
fractures [24]. Pseudofractures are most often seen in the ribs. It 
is uncommon to see pseudofractures in isolation at other sites such 
as femoral neck or pelvis. The bone scan provides a sensitive 
means of identifying pseudofractures, particularly in the ribs, where 
conventional radiology cannot detect the lesions [25]. However, 
lesions in the pelvis can on occasion be missed on the bone scan 
because of their symmetrical nature, or if they are obscured by 
bladder activity. 
In a comparative study with conventional radiography, all 15 
patients presenting with the disease were diagnosed by bone 
scan, whereas only 9 by radiography. Additionally, more pseudof-
ractures were appreciated by the bone scan [26]. In another study, 
5 patients suffering from osteomalacia had positive bone scans, 
follow up studies showed a reverse of bone scan images after 
appropriate treatment with calcium and vitamin D [27]. Other 
studies have also confirmed the better sensitivity of radiophos-
phate imaging over conventional radiography in the differential 
diagnosis between pseudofractures and metastatic disease when 
the lesions occur proximal to the knees and the elbows [28]. 
Pseudofracture detection is probably the most useful application 
of the bone scan in osteomalacia.
Primary hyperparathyroidism 
Primary hyperparathyroidism is a common disorder involving 
an increased secretion of parathyroid hormone that causes hy-
pophosphataemia and hypercalcaemia. Most cases are mild and 
asymptomatic, but in advanced cases, peptic ulcer, pseudogout, 
nephrolithiasis and less frequently, excessive bone resorption can 
be present. Radiographic changes are not usually present because 
the disease is diagnosed with increasing frequency and at an ear-
lier stage. Bone scan usually shows slight generalized increased 
uptake with high bone to soft tissue ratios. The degree of bone scan 
abnormality generally reflects the amount of skeletal involvement, 
and there is thus a wide range of scan appearances from normal 
to those mimicking severe renal osteodystrophy [29]. However, 
the bone scan usually appears normal and thus has no clear dia-
gnostic role in the routine evaluation of patients with suspected 
primary hyperparathyroidism [29]. The most sensitive radionuclide 
method seems to be the 24-hour total body retention measure-
ment [5]. Radiographic skeletal surveys are also normal in most 
cases, but specific changes such as subperiosteal erosions can 
occasionally be seen. The bone scan is the more sensitive of the 
two investigations and if scan appearances are not suggestive 
of metabolic bone disease then radiographs will invariably be 
normal [26]. A comparison between visually graded 99m Tc-HEDP 
images for metabolic characteristics and radiography showed 
that the first one detected 7 of 14 studied patients with primary 
hyperparathyroidism, whereas the latter detect 3 of them [26]. 
Despite apparently normal diphosphonate uptake on the bone 
scan by visual assessment, quantitative measurements (e.g. 24-hr 
WBR of diphosphonate) are frequently elevated as a result of mild 
diffuse increase in skeletal metabolism [1].
Ectopic calcification of the lungs and stomach can occur 
in advanced hyperparathyroidism, and can be detected with 
radiophosphate imaging [30]. Ectopic calcification is not a diag-
nostic feature; it can be present after the use of cytotoxic drugs, 
malignancy and in other conditions producing hypercalcaemia. 
The presences of focal abnormalities on the bone scan in primary 
hyperparathyroidism are uncommon but may be seen when Brown 
tumours are present, with chondrocalcinosis, or following vertebral 
collapse. In rare instances when a patient presents with aggressive, 
rapidly advancing primary hyperparathyroidism, multiple sites of 
ectopic calcification may be seen on the bone scan. 
Paget’s disease
Paget’s disease of bone is a common disorder in the elderly in 
which excessive production of structurally abnormal bone occurs. 
Paget’s disease is usually polyostotic, but may be monostotic; it 
is characterized in its initial phase by excess resorption of bone, 
which is followed by an intense osteoblastic response, with deposi-
tion of collagen in a mosaic pattern rather than the lamella arrange-
ment seen in normal bone. Pagetic bone is extremely vascular, 
and it has been suggested that this contributes to the bone pain. 
It is usually asymptomatic and normally is discovered incidentally 
after the detection of an elevated serum alkaline phosphatase, 
or a finding on X-ray or bone scan. The most common sites are 
the pelvis, spine, femur, tibia, and the skull, but any bone in the 
skeleton may be affected. The weight-bearing bones were most 
often symptomatic, lesions which appear normal radiographically 
but abnormal on the bone scan are generally asymptomatic [26].
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The bone scan appearances in Paget’s disease are often 
characteristic, with predominant feature being markedly increased 
uptake of tracer throughout most or all of the affected bone [31], 
except in osteoporosis circumscripta (lytic skull disease), in 
which, tracer uptake may only be increased in the margins of 
the lesion or after therapy where patchy focal uptake may be ob-
served [32]. Lesions in Paget’s disease may be clearly identified 
because of the clear delineation between normal and abnormal 
bones [33]. Nowadays, bone scan is recognized to be more 
sensitive than radiography in detecting sites of Paget’s disease 
in the skeleton, with the additional advantage of visualization of 
the whole skeleton in one exploration (Figure 3). Paget’s disease 
usually affects transverse spinous processes of the vertebrae. The 
affected vertebra has then a typical appearance that has been 
described as a “Mickey Mouse’’ sign because of the inverted 
triangular uptake distribution [34]. Other typical signs that have 
been described are the “black beard” sign (monostotic mandible 
disease) and the “short pants” sign (spine, pelvis and upper 
femoral disease) [35, 36].
The bone scan is generally of value in detecting complica-
tions of Paget’s disease such as fracture or sarcoma [33]. In 
Paget’s sarcoma, there is usually no evidence of increased uptake 
at the site of developing malignancy, unlike in uncomplicated 
Pagetic bone. Occasionally, a cold area within high uptake is pre-
sent [37, 38]; in this situation, conventional radiography together 
with computed tomography and biopsy should be obtained to 
confirm the diagnosis of malignant transformation [39]. Similarly, 
if osteosarcoma develops at a site of pagetic involvement it may 
be difficult to recognize on the diphosphonate scan. 67Ga scan 
is useful in confirming a diagnosis of sarcoma, because 67Ga 
uptake at the site of sarcoma is always greater than the relative 
Tc-diphosphonate uptake. Distinction between Paget’s disease 
and metastases is usually easy on bone scan when a typical 
Paget’s disease pattern is present [40]. Rarely, when bone scan 
appearances are atypical and radiography is unhelpful, a CT 
scan or biopsy will be required to establish a diagnosis. A single 
lesion on the bone scan is generally more difficult to interpret, 
but even in this situation the typical scan features are likely to 
differentiate monostotic Paget’s disease from other pathological 
conditions such as a sclerotic spinal metastasis from prostatic 
carcinoma. Bone scan is non-specific, where any doubt exists, 
radiographs should be obtained. 
After calcitonin [31] or bisphosphonate [41] therapy, bone 
scan shows alteration in uptake distribution, the uniform uptake 
distribution on the bone scan may change to patchy focal uptake. 
It usually corresponds to biochemical findings, although the scan 
changes occur more slowly [42]. Bone scan may be a better 
diagnostic indicator of long-term response than biochemical 
measurements. 
Bone scan is the most sensitive technique for Paget’s disease 
detection and staging, and should be used in primary evaluation 
[12]. Because of its high sensitivity and the possibility to check 
the whole skeleton in the same study, bone scan should be the 
imaging technique of choice [33], with radiography used to 
obtain supplementary information whenever required. In clinical 
practice, bone scintigraphy is the ideal screening test in cases of 
suspected Paget’s disease and in elderly patients with unexplained 
bone pain, bone deformity, or in patients with an elevated serum 
alkaline phosphatase. 
Osteoporosis
Osteoporosis is characterized by a decrease in bone mass with 
thinning of the cortex and trabeculae and a reduction in the number 
of trabeculae. Bone densitometry is the most diagnostic procedure 
for the detection of reduced bone mass. The bone scan has not 
been found to have an important role to play in the diagnosis of 
osteoporosis. This is a disorder where gradual change in bone 
mass may occur over many years, the bone scan appearances are 
usually normal and shows very low radiophosphate uptake in the 
skeleton, poor vertebral definition and low bone to soft tissue 
ratio [43]. However, the scan images may on occasion appear 
poor in quality because of relatively low bone uptake of tracer 
with a “washed-out” pattern activity in the axial and appendicular 
bones. It has been suggested that this occurs in severe or “end- 
-stage” osteoporosis caused by markedly reduced or even absent 
osteoblastic activity. Loss of vertebral height and closeness of the 
rib cage to pelvis in patients with multiple vertebral fractures may 
be observed in bone scan (Figure 4) [12]. These features are 
not diagnostic, but their presence may alert on the presence of 
osteoporosis. In practice the bone scan provides a less reliable 
means of diagnosing osteoporosis than radiography [26].
Osteoporotic bones are abnormally brittle and are at high risk 
of fractures from mild trauma. These are easily recognizable on 
the bone scan and are seen as focal areas of increased tracer 
uptake. If vertebral collapse is present, the classical appearance 
of a fracture in bone scan is a focal horizontal linear uptake on 
Figure 3. Patient E.J. 56 years old with Paget’s disease
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blood pool and static images at the site of the fracture. This in-
tense uptake usually decreases over a period of 6 to 18 months, 
and thus the scan is of value in assessing the age of vertebral 
collapse [26]. Even when scan appearances are quite typical of 
benign vertebral collapse, tumour cannot definitely be excluded 
and radiographs should be obtained. In the diagnosis of a patient 
with acute back pain with evidence of vertebral collapse on X-ray, 
the bone scan can help in the evaluation of the cause of pain. 
A normal scan would exclude a recent vertebral fracture, and 
other causes for back pain should then be considered. Bone scan 
can also suggest other causes of vertebral collapse or back pain 
such as metastases, infection, or Paget’s disease. In a study by 
Rico et al., bone to soft tissue uptake indices in recent osteoporotic 
vertebral collapse using bone scan were examined [44]. The study 
suggests that bone scan may be useful in monitoring response 
to therapy, but seems to have limited clinical yield. SPECT stud-
ies may help to increase image contrast in bone scan. It has the 
capacity to separate uptake above and below the areas of interest, 
which means that, in the spine, uptakes can be separately identi-
fied in the different sites of one vertebra. Bone scan plays a very 
important role in the early detection of clinical suspected frac-
tures with a negative or uncertain X-ray image. It may also allow the 
detection of clinically unsuspected fractures of the neck of femur, 
humerus, scapula, radius and ribs. In a study of Kobb et al., the 
bone scan was the only technique able to find unrecognised frac-
tures of pelvis that produced back pain similar to vertebral collapse 
pain [45]. Bone scan is capable of finding not only fractures but 
also fracture complication such as osteomyelitis and non-union. 
It is usually able to detect and to exclude alternative diagnosis or 
coexistent diseases at the same time. 
Miscellaneous conditions
There are many other conditions that can be considered under 
the heading of metabolic bone disease. In the majority of cases there 
is only limited experience with bone scanning. These conditions can 
cause generalized or focal alteration in skeletal metabolism: 
 — generalized skeletal involvement: seen in thyrotoxicosis, acro-
megaly, hypervitaminosis D, systemic mastocytosis, adult 
hypophosphatasia, and osteopetrosis;
 — focal skeletal involvement: seen in Engelmann’s disease (pro-
gressive diaphyseal dysplasia), fibrous dysplasia (Figures 4–5), 
osteopoikilosis, osteopathia striata, melorheostosis (benign 
sclerotic dysplasias), tumoural calcinosis, myositis ossificans, 
and scurvy.
Conclusions
Bone scintigraphy plays an important role in the management 
of metabolic bone disease. It’s most important features are the high 
sensitivity, the capacity to image the whole body and the capacity 
to show typical diagnostic patterns of abnormality.
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